{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:17:41Z","timestamp":1787584661374,"version":"build-2736575974"},"reference-count":44,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Taiwan Ministry of Health and Welfare","award":["MOHW113-TDU-B-222-134009"],"award-info":[{"award-number":["MOHW113-TDU-B-222-134009"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Liver transplantation (LT) is a promising treatment option for patients with hepatocellular carcinoma (HCC) comorbid with cirrhosis. However, HCC with portal vein tumor thrombosis (PVTT) remains an absolute contraindication for LT. This study aimed to analyze the outcomes of LT in patients with HCC plus portal vein thrombosis and further evaluate the impact of PVTT on the long-term outcomes of patients. Methods: Among the 501 patients who underwent LT for HCC between January 2000 and March 2023, 29 (5.8%) patients with HCC who had portal vein thrombosis were further analyzed. Of these 29 patients with portal vein thrombosis, 12 (41.4%) were preoperatively diagnosed with PVTT and underwent LT after receiving downstaging therapy. The remaining 17 (58.6%) patients were PVTT-free prior to LT. Results: Overall, the recurrence-free survival rates at 1, 3, and 5 years were 96.3%, 74.2%, and 74.2%, respectively, while the 1-, 3-, and 5-year overall survival rates were 82.4%, 74.2%, and 70.1%, respectively. However, patients with viable PVTT had significantly worse outcomes than those without viable PVTT (p = 0.030). The 5-year recurrence-free and overall survival rates for patients with viable PVTT were 57.5% and 57.0%, respectively. Conclusions: LT may still be a promising option for patients with HCC and PVTT after appropriate downstaging. However, caution should be adopted, as remnant viable PVTT might lead to unsatisfactory outcomes after transplantation.<\/jats:p>","DOI":"10.3390\/cancers17020188","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:56:22Z","timestamp":1736337382000},"page":"188","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Disadvantage of Viable Portal Vein Tumor Thrombosis in Liver Transplantation for Advanced Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"17","author":[{"given":"Kun-Ming","family":"Chan","sequence":"first","affiliation":[{"name":"Department of General Surgery, Chang Gung Transplantation Institute, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Chang Gung Transplantation Institute, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8830-3679","authenticated-orcid":false,"given":"Hao-Chien","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Chang Gung Transplantation Institute, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6075-8786","authenticated-orcid":false,"given":"Jin-Chiao","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Chang Gung Transplantation Institute, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsien","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Chang Gung Transplantation Institute, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Chang Gung Transplantation Institute, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Han","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Chang Gung Transplantation Institute, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Fang","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Chang Gung Transplantation Institute, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Jung","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Chang Gung Transplantation Institute, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3583-2048","authenticated-orcid":false,"given":"Hong-Shiue","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Chang Gung Transplantation Institute, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chen","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Chang Gung Transplantation Institute, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan 33302, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Chan, K.M., and Lee, W.C. (2024). Liver transplantation for advanced hepatocellular carcinoma: Controversy over portal vein tumor thrombosis. Biomed. J.","DOI":"10.1016\/j.bj.2024.100757"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/jamasurg.2023.6083","article-title":"Liver Transplant as a Treatment of Primary and Secondary Liver Neoplasms","volume":"159","author":"Gorji","year":"2024","journal-title":"JAMA Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(11)70175-9","article-title":"Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report","volume":"13","author":"Clavien","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jhep.2023.03.032","article-title":"Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation?","volume":"78","author":"Soin","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2967\/jnumed.117.199752","article-title":"(90)Y Radioembolization for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Long-Term Outcomes in a 185-Patient Cohort","volume":"59","author":"Abouchaleh","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/cncr.21237","article-title":"Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus","volume":"104","author":"Hata","year":"2005","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/liv.13191","article-title":"Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area","volume":"37","author":"Im","year":"2017","journal-title":"Liver Int."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhang, X.F., Lai, L., Zhou, H., Mo, Y.J., Lu, X.Q., Liu, M., Lu, Y.X., and Hou, E.C. (2022). Stereotactic body radiotherapy plus transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma patients with portal vein tumour thrombus: A meta-analysis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0268779"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver","volume":"35","author":"Bruix","year":"2001","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-0030-1247133","article-title":"Current strategy for staging and treatment: The BCLC update and future prospects","volume":"30","author":"Forner","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1056\/NEJMp1510020","article-title":"Shared Decision Making--Finding the Sweet Spot","volume":"374","author":"Fried","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bj.2019.04.001","article-title":"Advantage of early liver transplantation whenever indicated for hepatocellular carcinoma recurrence after primary liver resection","volume":"42","author":"Chan","year":"2019","journal-title":"Biomed. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4240\/wjgs.v12.i1.17","article-title":"Outcomes associated with the intention of loco-regional therapy prior to living donor liver transplantation for hepatocellular carcinoma","volume":"12","author":"Wu","year":"2020","journal-title":"World J. Gastrointest. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/SLA.0b013e31820508f1","article-title":"Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion","volume":"253","author":"DuBay","year":"2011","journal-title":"Ann. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/lt.21445","article-title":"Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center","volume":"14","author":"Lee","year":"2008","journal-title":"Liver Transpl."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000106910","article-title":"Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series","volume":"25","author":"Sugawara","year":"2007","journal-title":"Dig. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00534-009-0162-y","article-title":"Liver transplantation for hepatocellular carcinoma: The Kyoto experience","volume":"17","author":"Takada","year":"2010","journal-title":"J. Hepatobil. Pancreat. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/lt.24782","article-title":"The clinical outcomes of patients with portal vein tumor thrombi after living donor liver transplantation","volume":"23","author":"Choi","year":"2017","journal-title":"Liver Transpl."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/lt.24610","article-title":"Macrovascular invasion is not an absolute contraindication for living donor liver transplantation","volume":"23","author":"Lee","year":"2017","journal-title":"Liver Transpl."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1097\/TP.0000000000003162","article-title":"Experience With LDLT in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis Postdownstaging","volume":"104","author":"Soin","year":"2020","journal-title":"Transplantation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S1665-2681(19)30797-5","article-title":"Portal vein thrombosis: What is new?","volume":"14","author":"Uribe","year":"2015","journal-title":"Ann. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/lt.25345","article-title":"Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: The A-VENA Criteria","volume":"25","author":"Sherman","year":"2019","journal-title":"Liver Transpl."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2021.07.033","article-title":"Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium","volume":"161","author":"Mehta","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1111\/j.1600-6143.2008.02409.x","article-title":"Liver transplantation for hepatocellular carcinoma: Results of down-staging in patients initially outside the Milan selection criteria","volume":"8","author":"Ravaioli","year":"2008","journal-title":"Am. J. Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/01.tp.0000446267.19148.21","article-title":"Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation","volume":"97","author":"Sharr","year":"2014","journal-title":"Transplantation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.27752","article-title":"Downstaging of hepatocellular cancer before liver transplant: Long-term outcome compared to tumors within Milan criteria","volume":"61","author":"Yao","year":"2015","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/lt.26257","article-title":"Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study","volume":"27","author":"Serenari","year":"2021","journal-title":"Liver Transpl."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2017.12.026","article-title":"Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion","volume":"68","author":"Spreafico","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.radonc.2015.11.019","article-title":"Clinical impact of combined transarterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: An external validation study","volume":"118","author":"Yu","year":"2016","journal-title":"Radiother. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Chen, M.Y., Wang, Y.C., Wu, T.H., Lee, C.F., Wu, T.J., Chou, H.S., Tsang, N.M., Chan, K.M., and Lee, W.C. (2016). Efficacy of External Beam Radiation-Based Treatment plus Locoregional Therapy for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombosis. Biomed. Res. Int., 2016.","DOI":"10.1155\/2016\/6017406"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"966","DOI":"10.21037\/hbsn-23-410","article-title":"Proton beam therapy for downstaging hepatocellular carcinoma with lobar portal vein tumor thrombosis to living donor liver transplantation","volume":"12","author":"Chen","year":"2023","journal-title":"Hepatobil. Surg. Nutr."},{"key":"ref_37","first-page":"EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Lau","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1007\/s12328-021-01521-4","article-title":"Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy","volume":"14","author":"Dehghan","year":"2021","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1097\/TXD.0000000000000814","article-title":"Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research","volume":"4","author":"Gassmann","year":"2018","journal-title":"Transplant. Direct"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/ajt.15617","article-title":"Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?","volume":"20","author":"Nordness","year":"2020","journal-title":"Am. J. Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ajt.2024.04.007","article-title":"Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study","volume":"24","author":"Guo","year":"2024","journal-title":"Am. J. Transplant."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/2\/188\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:25:15Z","timestamp":1759919115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/2\/188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["cancers17020188"],"URL":"https:\/\/doi.org\/10.3390\/cancers17020188","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]}}}